SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Guidelines for follow-up of women at high risk for inherited breast cancer: Consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer

Møller, P; Evans, G; Haites, N; Vasen, H; Reis, MM; Anderson, E; Apold, J; Hodgson, S; Eccles, D; Olsson, H; et al. Møller, P; Evans, G; Haites, N; Vasen, H; Reis, MM; Anderson, E; Apold, J; Hodgson, S; Eccles, D; Olsson, H; Stoppa-Lyonnet, D; Chang-Claude, J; Morrison, PJ; Bevilacqua, G; Heimdal, K; Maehle, L; Lalloo, F; Gregory, H; Preece, P; Borg, A; Nevin, NC; Caligo, M; Steel, CM (1999) Guidelines for follow-up of women at high risk for inherited breast cancer: Consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. DISEASE MARKERS, 15 (1-3). 207 - 211 (5). ISSN 0278-0240 https://doi.org/10.1155/1999/920109
SGUL Authors: Hodgson, Shirley Victoria

[img]
Preview
["document_typename_application/pdf; charset=binary" not defined] Published Version
Download (34kB) | Preview

Abstract

Protocols for activity aiming at early diagnosis and treatment of inherited breast or breast-ovarian cancer have been reported. Available reports on outcome of such programmes are considered here. It is concluded that the ongoing activities should continue with minor modifications. Direct evidence of a survival benefit from breast and ovarian screening is not yet available. On the basis of expert opinion and preliminary results from intervention programmes indicating good detection rates for early breast cancers and 5-year survival concordant with early diagnosis, we propose that women at high risk for inherited breast cancer be offered genetic counselling, education in ‘breast awareness’ and annual mammography and clinical expert examination from around 30 years of age. Mammography every second year may be sufficient from 60 years on. BRCA1 mutation carriers may benefit from more frequent examinations and cancer risk may be reduced by oophorectomy before 40–50 years of age. We strongly advocate that all activities should be organized as multicentre studies subjected to continuous evaluation to measure the effects of the interventions on long-term mortality, to match management options more precisely to individual risks and to prepare the ground for studies on chemoprevention.

Item Type: Article
Additional Information: PubMed ID: 10595280
Keywords: Age Factors, BRCA2 Protein, Breast Neoplasms, Breast Neoplasms, Male, DNA Mutational Analysis, Female, Follow-Up Studies, Genes, BRCA1, Genetic Counseling, Genetic Predisposition to Disease, Genetic Testing, Humans, Male, Mammography, Mastectomy, Neoplasm Proteins, Neoplastic Syndromes, Hereditary, Oncogenes, Ovarian Neoplasms, Patient Education as Topic, Physical Examination, Pilot Projects, Risk, Transcription Factors, Science & Technology, Life Sciences & Biomedicine, Biotechnology & Applied Microbiology, Genetics & Heredity, Medicine, Research & Experimental, Pathology, Research & Experimental Medicine, BIOTECHNOLOGY & APPLIED MICROBIOLOGY, GENETICS & HEREDITY, MEDICINE, RESEARCH & EXPERIMENTAL, PATHOLOGY, OVARIAN-CANCER, FAMILY HISTORY, MANAGEMENT, BRCA1
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) > Cell Sciences (INCCCS)
Journal or Publication Title: DISEASE MARKERS
ISSN: 0278-0240
Related URLs:
Dates:
DateEvent
1 October 1999Published
Web of Science ID: WOS:000083988300069
Download EPMC Full text (PDF)
Download EPMC Full text (HTML)
URI: https://openaccess.sgul.ac.uk/id/eprint/103818
Publisher's version: https://doi.org/10.1155/1999/920109

Actions (login required)

Edit Item Edit Item